| Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes (NCT01272219) | Novo Nordisk A/S | 2011-06-01 |
| Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes (NCT01272232) | Novo Nordisk A/S | 2011-06-01 |
| Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus (NCT01364428) | Novo Nordisk A/S | 2011-06-01 |
| Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens (NCT01365507) | Novo Nordisk A/S | 2011-06-01 |
| Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes (NCT01336023) | Novo Nordisk A/S | 2011-05-23 |
| Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients (NCT01333111) | Novo Nordisk A/S | 2011-04-27 |
| Safety of NNC 0123-0000-0338 in Healthy Subjects (NCT01334034) | Novo Nordisk A/S | 2011-04-11 |
| A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors (NCT01830712) | Novo Nordisk A/S | 2011-04-01 |
| Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone (NCT01327924) | Novo Nordisk A/S | 2011-04-01 |
| A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India (NCT01351922) | Novo Nordisk A/S | 2011-04-01 |
| Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus (NCT01326026) | Novo Nordisk A/S | 2011-03-01 |
| Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes (NCT01324505) | Novo Nordisk A/S | 2011-03-01 |
| Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone (NCT01215435) | Novo Nordisk A/S | 2011-03-01 |
| Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects (NCT01319240) | Novo Nordisk A/S | 2011-03-01 |
| Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency (NCT01312636) | Novo Nordisk A/S | 2011-03-01 |
| Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes (NCT01288326) | Novo Nordisk A/S | 2011-02-01 |
| A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1 (NCT01296438) | Novo Nordisk A/S | 2011-02-01 |
| Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects (NCT01242826) | Novo Nordisk A/S | 2011-02-01 |
| Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis (NCT01282255) | Novo Nordisk A/S | 2011-02-01 |
| A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis (NCT01223911) | Novo Nordisk A/S | 2011-01-01 |
| Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (NCT01272193) | Novo Nordisk A/S | 2011-01-01 |
| Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients (NCT01288391) | Novo Nordisk A/S | 2011-01-01 |
| Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes (NCT01269606) | Novo Nordisk A/S | 2011-01-01 |
| Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects (NCT01272973) | Novo Nordisk A/S | 2011-01-01 |
| Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756 (NCT01278160) | Novo Nordisk A/S | 2011-01-01 |
| Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency (NCT01253811) | Novo Nordisk A/S | 2011-01-01 |
| Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects (NCT01272206) | Novo Nordisk A/S | 2011-01-01 |
| Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia (NCT01285089) | Novo Nordisk A/S | 2010-12-01 |
| Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency (NCT01230021) | Novo Nordisk A/S | 2010-11-01 |
| A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India (NCT01212133) | Novo Nordisk A/S | 2010-11-01 |
| A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543 (NCT01238367) | Novo Nordisk A/S | 2010-11-01 |
| Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents (NCT01245374) | Novo Nordisk A/S | 2010-11-01 |
| Changing Diabetes® World Tour (NCT01437072) | Novo Nordisk A/S | 2010-11-01 |
| Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B (NCT01220141) | Novo Nordisk A/S | 2010-11-01 |
| Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes (NCT01232491) | Novo Nordisk A/S | 2010-10-29 |
| Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (NCT01228669) | Novo Nordisk A/S | 2010-10-25 |
| Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors (NCT01234545) | Novo Nordisk A/S | 2010-10-01 |
| Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen (NCT01165684) | Novo Nordisk A/S | 2010-10-01 |
| Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes (NCT01180530) | Novo Nordisk A/S | 2010-10-01 |
| Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin Analogues (NCT01585506) | Novo Nordisk A/S | 2010-09-20 |
| First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis (NCT01208506) | Novo Nordisk A/S | 2010-09-01 |
| Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes (NCT01226966) | Novo Nordisk A/S | 2010-09-01 |
| Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A (NCT01205724) | Novo Nordisk A/S | 2010-09-01 |
| Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (NCT01179048) | Novo Nordisk A/S | 2010-08-31 |
| A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes (NCT01174303) | Novo Nordisk A/S | 2010-08-01 |
| Comparison of Two Identical NN1250 Formulations in Healthy Volunteers (NCT01193387) | Novo Nordisk A/S | 2010-08-01 |
| Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes (NCT01173926) | Novo Nordisk A/S | 2010-07-01 |
| Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers (NCT01153997) | Novo Nordisk A/S | 2010-06-01 |
| A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes (NCT01138488) | Novo Nordisk A/S | 2010-06-01 |
| Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™) (NCT01135992) | Novo Nordisk A/S | 2010-06-01 |
| Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A (NCT01138501) | Novo Nordisk A/S | 2010-06-01 |
| A Trial Comparing the Effect of NN1250 After Different Routes of Injection in Healthy Subjects (NCT01151072) | Novo Nordisk A/S | 2010-06-01 |
| A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes (NCT01135927) | Novo Nordisk A/S | 2010-06-01 |
| A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes (NCT01154881) | Novo Nordisk A/S | 2010-06-01 |
| A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes (NCT01114542) | Novo Nordisk A/S | 2010-05-03 |
| A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes (NCT01134224) | Novo Nordisk A/S | 2010-05-01 |
| A Comparison Between Two Formulations of NN5401 in Healthy Subjects (NCT01125553) | Novo Nordisk A/S | 2010-05-01 |
| Observational Study to Investigate the Occurrence of Bleeding in Postmenopausal Women Treated With Estradiol/NETA for 12 Months (NCT01076621) | Novo Nordisk A/S | 2010-05-01 |
| Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment (NCT01123980) | Novo Nordisk A/S | 2010-05-01 |
| A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes (NCT01121276) | Novo Nordisk A/S | 2010-04-01 |
| A Trial Investigating NN1218 in Subjects With Type 1 Diabetes (NCT01121289) | Novo Nordisk A/S | 2010-04-01 |
| A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects (NCT01087645) | Novo Nordisk A/S | 2010-03-12 |
| Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (NCT01068665) | Novo Nordisk A/S | 2010-03-01 |
| Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs (NCT01068652) | Novo Nordisk A/S | 2010-03-01 |
| GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus (NCT01950650) | Novo Nordisk A/S | 2010-03-01 |
| An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients (NCT01077570) | Novo Nordisk A/S | 2010-03-01 |
| Comparison of Two Vaginal Tablets, Produced at Different Sites, in Postmenopausal Women With Atrophic Vaginitis (NCT01085877) | Novo Nordisk A/S | 2010-03-01 |
| Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (NCT01076647) | Novo Nordisk A/S | 2010-03-01 |
| Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects (NCT01082406) | Novo Nordisk A/S | 2010-03-01 |
| Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes (NCT01079234) | Novo Nordisk A/S | 2010-03-01 |
| Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes (NCT01074268) | Novo Nordisk A/S | 2010-02-01 |
| Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (NCT01059799) | Novo Nordisk A/S | 2010-02-01 |
| Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes (NCT01076634) | Novo Nordisk A/S | 2010-02-01 |
| Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis (NCT01038674) | Novo Nordisk A/S | 2010-02-01 |
| Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (NCT01068678) | Novo Nordisk A/S | 2010-02-01 |
| A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes (NCT01059812) | Novo Nordisk A/S | 2010-02-01 |
| An Observational Study on Treatment Compliance by Children Treated With Growth Hormone (NCT01068639) | Novo Nordisk A/S | 2010-02-01 |
| A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers (NCT01044108) | Novo Nordisk A/S | 2010-01-05 |
| Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin (NCT01046110) | Novo Nordisk A/S | 2010-01-01 |
| Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes (NCT01045447) | Novo Nordisk A/S | 2010-01-01 |
| Effect of NN5401 in Japanese Subjects With Type 1 Diabetes (NCT01051102) | Novo Nordisk A/S | 2010-01-01 |
| Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes (NCT01045707) | Novo Nordisk A/S | 2010-01-01 |
| The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin (NCT01043510) | Novo Nordisk A/S | 2010-01-01 |
| A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects (NCT01037582) | Novo Nordisk A/S | 2009-12-17 |
| A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes (NCT01030926) | Novo Nordisk A/S | 2009-12-01 |
| Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing (NCT01110928) | Novo Nordisk A/S | 2009-11-26 |
| Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes (NCT01009580) | Novo Nordisk A/S | 2009-11-05 |
| Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes (NCT01006291) | Novo Nordisk A/S | 2009-11-01 |
| Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes (NCT00943501) | Novo Nordisk A/S | 2009-11-01 |
| A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes (NCT01028404) | Novo Nordisk A/S | 2009-11-01 |
| An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE) (NCT01018238) | Novo Nordisk A/S | 2009-11-01 |
| Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment (NCT01022762) | Novo Nordisk A/S | 2009-11-01 |
| A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function (NCT01006057) | Novo Nordisk A/S | 2009-11-01 |
| Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 (NCT00984126) | Novo Nordisk A/S | 2009-10-26 |
| Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics (NCT00992537) | Novo Nordisk A/S | 2009-10-01 |
| Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics (NCT01002768) | Novo Nordisk A/S | 2009-10-01 |
| Observational Study of the Safety and Efficacy of Norditropin® in Adult Patients With Growth Hormone Deficiency (NCT01109017) | Novo Nordisk A/S | 2009-10-01 |
| A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics (NCT00993304) | Novo Nordisk A/S | 2009-10-01 |
| Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 (NCT00978380) | Novo Nordisk A/S | 2009-09-21 |
| A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers (NCT00978393) | Novo Nordisk A/S | 2009-09-16 |